BioSpace

Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor

Merck continues to diversify its cancer efforts as the clock ticks down on Keytruda’s patent, picking up rights to a preclinical oncology asset in a deal that could exceed $2 billion.

Por BioSpace

1 minuto de lectura
Compartir
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas